Recent studies have indicated that dysregulation of the adenosine monophosphate-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR)/interferon regulatory factor 5 (IRF5) signaling pathway is implicated in neuroinflammation and the pathogenesis of AD (Zhu et al., 2016, Li et al., 2020). Here, IRF5 is linked to Alzheimer disease.